US equities
|
NVDA
$239.24
▲+0.14%
MU
$1,045.56
▼-1.73%
SPCX
$171.92
▲+0.49%
AMD
$649.42
▲+2.80%
MRVL
$287.01
▲+5.81%
AVGO
$375.81
▲+3.67%
INTC
$112.50
▼-3.18%
MSFT
$529.30
▲+0.78%
NVDA
$239.24
▲+0.14%
MU
$1,045.56
▼-1.73%
SPCX
$171.92
▲+0.49%
AMD
$649.42
▲+2.80%
MRVL
$287.01
▲+5.81%
AVGO
$375.81
▲+3.67%
INTC
$112.50
▼-3.18%
MSFT
$529.30
▲+0.78%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Emergent Health Corp
(OP:
EMGE
)
0.0001
UNCHANGED
Delayed Quote
Updated: 9:30 AM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Emergent Health Corp
< Previous
1
2
3
Next >
Apollo Biowellness, Inc./Resonate Blends, Inc., Provides Corporate Update Following Closing of Share Exchange Agreement
May 13, 2024
North Bergen, New Jersey--(Newsfile Corp. - May 13, 2024) - Apollo Biowellness, Inc., /Resonate Blends, Inc. (OTC Pink: KOAN) ("Resonate...
Via
Newsfile
Resonate Blends Executes a Share Exchange Agreement With Emergent Health Corp.
March 15, 2024
Via
ACCESSWIRE
Emergent Health and Apollo Biowellness Announce Strategic Collaboration
May 23, 2023
Emergent Health Corp. (OTC: EMGE), a curator, developer, and marketer of products in the Regenerative Health Space announced today that it will be collaborating with Apollo Biowellness, Inc., the...
Via
TheNewswire.com
Topics
Initial Public Offering
Emergent Health and Apollo Biowellness Announce Strategic Collaboration
May 23, 2023
Former L'Oréal President and Emergent’s CEO promoted to Emergent Chairman of the Board successor Announced
Via
News Direct
Topics
Initial Public Offering
Emergent Health Executes Term Sheet and Engagement Letter with Boustead Securities to roll up its Subsidiary, Evolutionary Biologics and other regenerative medicine and products companies
May 18, 2023
Emergent Health Executes Term Sheet and Engagement Letter with Boustead Securities to roll up its Subsidiary, Evolutionary Biologics and other regenerative medicine and products companies
Via
News Direct
Topics
Initial Public Offering
Regulatory Compliance
Emergent Health Executes Term Sheet and Engagement Letter with Boustead Securities to roll up its Subsidiary, Evolutionary Biologics and other regenerative medicine and products companies
May 18, 2023
Emergent Health Corp. (OTC: EMGE), a curator, developer, and marketer of products in the Regenerative Health Space announced that it has executed a Term Sheet and Engagement Letter with Boustead...
Via
TheNewswire.com
Topics
Initial Public Offering
Regulatory Compliance
Former L'Oréal President Jim Morrison, Chief Executive Officer of Emergent Health Reports Quarter over Quarter Revenue Increase of Over 2300%
May 16, 2023
Emergent Health Corp. (OTC: EMGE), a curator, developer, and marketer of products in the Regenerative Health Space announced revenues of $340,531 for the quarter ended March 31, 2023, as compared to...
Via
TheNewswire.com
Former L'Oréal President Jim Morrison, Chief Executive Officer of Emergent Health Reports Quarter over Quarter Revenue Increase of Over 2300%
May 16, 2023
Former L'Oréal President Jim Morrison, Chief Executive Officer of Emergent Health Reports Quarter over Quarter Revenue Increase of Over 2300%
Via
News Direct
Emergent Health Subsidiary Evolutionary Biologics Executes Product Manufacturing Agreement with Major Player in the Regenerative Medicine Space
May 11, 2023
Emergent Health Corp. (OTC: EMGE), a curator, developer, and marketer of products in the Regenerative Health Space announced that its subsidiary Evolutionary Biologics, Inc. (“EvoBio”), a developer,...
Via
TheNewswire.com
Topics
Initial Public Offering
Emergent Health Subsidiary Evolutionary Biologics Executes Product Manufacturing Agreement with Major Player in the Regenerative Medicine Space
May 11, 2023
Expected to Generate at least $2 Million in New Revenue
Via
News Direct
Emergent Health Subsidiary PharmaZu Retains BF Borgers to Audit its Financial Statement as required by the Engagement Letter with Boustead Securities
May 09, 2023
Emergent Health Subsidiary PharmaZu Retains BF Borgers to Audit its Financial Statement as required by the Engagement Letter with Boustead Securities
Via
News Direct
Topics
Initial Public Offering
Emergent Health Subsidiary PharmaZu Retains BF Borgers to Audit its Financial Statement as required by the Engagement Letter with Boustead Securities
May 09, 2023
Via
TheNewswire.com
Topics
Initial Public Offering
Emergent Health to spin out subsidiary PharmaZu to its Shareholders pursuant to an IPO underwritten by a Nationally Recognized Investment Banking Firm
May 04, 2023
Emergent Health to spin out subsidiary PharmaZu to its Shareholders pursuant to an IPO underwritten by a Nationally Recognized Investment Banking Firm
Via
News Direct
Topics
Initial Public Offering
Emergent Health to spin out subsidiary PharmaZu to its Shareholders pursuant to an IPO underwritten by a Nationally Recognized Investment Banking Firm
May 04, 2023
Emergent Health Corp. (OTC: EMGE), a curator, developer, and marketer of products in the Regenerative Health Space announced today that it has executed a Term Sheet for a firm committed underwriting...
Via
TheNewswire.com
Topics
Initial Public Offering
Emergent Health Announces Its Return to the “Pink Current Information” Tier on OTC Markets
May 03, 2023
Emergent Health Announces Its Return to the “Pink Current Information” Tier on OTC Markets
Via
News Direct
Emergent Health Announces Its Return to the “Pink Current Information” Tier on OTC Markets
May 03, 2023
Emergent Health Corp. (OTC: EMGE), a curator, developer, and marketer of products in the Regenerative Health Space, is pleased to announce that it has regained its “Pink Current Information” status...
Via
TheNewswire.com
Former L'Oréal President Jim Morrison, Chief Executive Officer of Emergent Health Corp. Reports Year to Year Revenue Increase of Over 380% and Quarter to Quarter Revenue Increase of Over 100%
May 02, 2023
Former L'Oréal President Jim Morrison, Chief Executive Officer of Emergent Health Corp. Reports Year to Year Revenue Increase of Over 380% and Quarter to Quarter Revenue Increase of Over 100%
Via
News Direct
Former L'Oréal President Jim Morrison, Chief Executive Officer of Emergent Health Corp. Reports Year to Year Revenue Increase of Over 380% and Quarter to Quarter Revenue Increase of Over 100%
May 02, 2023
Emergent Health Corp. (OTC: EMGE), a curator, developer, and marketer of products in the Regenerative Health Space announced today announced revenues of $373,406 for the quarter ended December 31, 2022...
Via
TheNewswire.com
Topics
Intellectual Property
Emergent Announces 'Month in Review' with CEO Jim Morrison
March 02, 2023
Via
ACCESSWIRE
Emergent Health Announces Revenue Forecast of $16 Million & Introduces ‘MAXIMUS Men’s Health’
February 28, 2023
Via
ACCESSWIRE
Emergent Health (EMGE) Completes Acquisition of Nanosthetic - Adding $3.5 Million to its Growing Revenue Streams
February 23, 2023
Via
ACCESSWIRE
Emergent Health (EMGE) Executes "Letter of Intent" to Acquire Privately Held Company with a total of $5.4 Million in Current Revenues
February 21, 2023
Via
ACCESSWIRE
(EMGE) Emergent Health Enters Acquisition Talks with Revenue-Producing Medical Company
February 17, 2023
Via
ACCESSWIRE
Emergent Health Announces that Retail Power Hitter and Former Kraft Foods Director of National Accounts, Charlie McMenamin, Plans Product Placements in Nation's Biggest Retail Companies
February 14, 2023
Via
ACCESSWIRE
Emergent Projects $3.5 Million in Revenues With Acquisition of Nanosthetic Corp. Fueling Evolutionary Biologics
February 07, 2023
Via
ACCESSWIRE
Emergent Health Appoints Former Kraft Foods Director of National Accounts Charlie McMenamin to Its Board of Directors
January 31, 2023
Via
ACCESSWIRE
Emergent Executes "Letter of Intent" to Acquire Nanosthetic, a Biologics Company That Manufacturers Products to be Sold and Marketed by Evolutionary Biologics
January 26, 2023
Via
ACCESSWIRE
Emergent Intends to Become a Fully Reporting SEC Issuer and List its Shares on the OTCQB
January 10, 2023
Via
ACCESSWIRE
Emergent Reports Revenues of Approximately $408,000 for the Quarter Ended December 31st, 2022, as Compared to Approximately $185,000 for the Quarter Ended September 30, 2022, an Increase of Over 100%
January 05, 2023
Via
ACCESSWIRE
Emergent Subsidiary "PharmaZu" Launches E-Commerce Online Platform Entering the Estimated $8.5 Billion-Dollar Online Pet Medicine Industry
January 03, 2023
Via
ACCESSWIRE
< Previous
1
2
3
Next >
